Variation in NGFB is associated with primary affective disorders in women

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 4, 2011, Pages 401-412

  Cui, Donghong ^a,b   Zhang, Huiping ^a,b   Yang, Bao Zhu ^a,b   Listman, Jennifer B ^a   Li, Dawei ^a   Price, Lawrence H ^c   Carpenter, Linda L ^c   Tyrka, Audrey R ^c   Anton, Raymond F ^d   Kranzler, Henry R ^e   Gelernter, Joel ^a,b,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c BROWN UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Affective disorder; Association study; Nerve growth factor ; NGFB; Sex specific; Substance dependence

Indexed keywords

ALCOHOL; CENTRAL STIMULANT AGENT; COCAINE; GLUTAMATE DECARBOXYLASE; NERVE GROWTH FACTOR BETA SUBUNIT; OPIATE; SEDATIVE AGENT;

ADULT; AGORAPHOBIA; ALCOHOLISM; ARTICLE; ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EMPIRICISM; EUROPEAN AMERICAN; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OPIATE ADDICTION; PANIC; PATHOLOGICAL GAMBLING; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA; TOBACCO;

CASE-CONTROL STUDIES; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MOOD DISORDERS; NERVE GROWTH FACTOR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 79955077117     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31175     Document Type: Article

References (40)

1. Alleva E, Santucci D. 2001. Psychosocial vs. "physical" stress situations in rodents and humans: Role of neurotrophins. Physiol Behav 73(3): 313-320.
2. Aloe L, Alleva E, Fiore M. 2002. Stress and nerve growth factor: Findings in animal models and humans. Pharmacol Biochem Behav 73(1): 159-166.
3. Altemus M. 2006. Sex differences in depression and anxiety disorders: Potential biological determinants. Horm Behav 50(4): 534-538.
4. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA. 2003. Electroconvulsive stimuli alter nerve growth factor but not brain-derived neurotrophic factor concentrations in brains of a rat model of depression. Neuropeptides 37(1): 51-56.
5. Angelucci F, Ricci V, Pomponi M, Conte G, Mathe AA, Attilio Tonali P, Bria P. 2007. Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 21(8): 820-825.
6. Angelucci F, Ricci V, Spalletta G, Pomponi M, Tonioni F, Caltagirone C, Bria P. 2008. Reduced serum concentrations of nerve growth factor, but not brain-derived neurotrophic factor, in chronic cannabis abusers. Eur Neuropsychopharmacol 18(12): 882-887.
7. Barde YA. 1990. The nerve growth factor family. Prog Growth Factor Res 2(4): 237-248.
8. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L. 2000. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med Hypotheses 55(3): 199-207.
9. Brown SA, Schuckit MA. 1988. Changes in depression among abstinent alcoholics. J Stud Alcohol 49(5): 412-417.
10. Chen G, Manji HK. 2006. The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Curr Opin Psychiatry 19(3): 313-323.
11. Cirulli F, Francia N, Branchi I, Antonucci MT, Aloe L, Suomi SJ, Alleva E. 2009. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrinology 34(2): 172-180.
12. Davies AM. 2000. Neurotrophins: More to NGF than just survival. Curr Biol 10(10): R374-R376.
13. Davis L, Uezato A, Newell JM, Frazier E. 2008. Major depression and comorbid substance use disorders. Curr Opin Psychiatry 21(1): 14-18.
14. Drevets WC, Savitz J, Trimble M. 2008. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13(8): 663-681.
15. Evanno G, Regnaut S, Goudet J. 2005. Detecting the number of clusters of individuals using the software STRUCTURE: A simulation study. Mol Ecol 14(8): 2611-2620.
16. First M, Spitzer RL, Gibbon M, Williams JB. 1997. Structured Clinical Interview for DSM-IV AXIS I Disorders (Clinician Version) SCID-I Administration Booklet. Washington, DC American Psychiatric Publishing, Inc.
17. Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, True WR, Jacob T, Tsuang MT, Eisen SA. 2002. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: Contribution of antisocial personality disorder in men. Arch Gen Psychiatry 59(12): 1125-1132.
18. Goel N, Bale TL. 2009. Examining the intersection of sex and stress in modeling neuropsychiatric disorders. J Neuroendocrinol 21:415-420.
19. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. 2004. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on alcohol and related conditions. Arch Gen Psychiatry 61(8): 807-816.
20. Hellweg R, Lang UE, Nagel M, Baumgartner A. 2002. Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 7(6): 604-608.
21. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA, Binder EB, Cubells J, Ehlers CL, Gelernter J, et al., 2008. Addictions biology: Haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 43(5): 505-515.
22. Katoh-Semba R, Semba R, Kashiwamata S, Kato K. 1990. Influences of neonatal and adult exposures to testosterone on the levels of the beta-subunit of nerve growth factor in the neural tissues of mice. Brain Res 522(1): 112-117.
23. Lang UE, Hellweg R, Bajbouj M, Gaus V, Sander T, Gallinat J. 2008. Gender-dependent association of a functional NGF polymorphism with anxiety-related personality traits. Pharmacopsychiatry 41(5): 196-199.
24. Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237(4819): 1154-1162.
25. Levi-Montalcini R, Angeletti PU. 1968. Nerve growth factor. Physiol Rev 48(3): 534-569.
26. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. 2009. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 373(9659): 234-239.
27. Marais L, van Rensburg SJ, van Zyl JM, Stein DJ, Daniels WM. 2008. Maternal separation of rat pups increases the risk of developing depressive-like behavior after subsequent chronic stress by altering corticosterone and neurotrophin levels in the hippocampus. Neurosci Res 61(1): 106-112.
28. Markou A, Kosten TR, Koob GF. 1998. Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18(3): 135-174.
29. Nakamura MM, Overall JE, Hollister LE, Radcliffe E. 1983. Factors affecting outcome of depressive symptoms in alcoholics. Alcohol Clin Exp Res 7(2): 188-193.
30. Niciu MJ, Chan G, Gelernter J, Arias AJ, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR. 2009. Subtypes of major depression in substance dependence. Addiction 104:1700-1709.
31. Phillips ML, Ladouceur CD, Drevets WC. 2008. A neural model of voluntary and automatic emotion regulation: Implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol Psychiatry 13(9): 829, 833-57.
32. Pierucci-Lagha A, Gelernter J, Feinn R, Cubells JF, Pearson D, Pollastri A, Farrer L, Kranzler HR. 2005. Diagnostic reliability of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug Alcohol Depend 80(3): 303-312.
33. Ross HE, Swinson R, Doumani S, Larkin EJ. 1995. Diagnosing comorbidity in substance abusers: A comparison of the test-retest reliability of two interviews. Am J Drug Alcohol Abuse 21(2): 167-185.
34. Schuckit MA. 2006. Comorbidity between substance use disorders and psychiatric conditions. Res Rep 101:76-88.
35. Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, et al., 2009. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 66(7): 785-795.
36. Sofroniew MV, Howe CL, Mobley WC. 2001. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24:1217-1281.
37. Spitzer RL, Williams JB, Gibbon M, First MB. 1992. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49(8): 624-629.
38. Uhl GR, Grow RW. 2004. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 61(3): 223-229.
39. Wada A. 2009. Lithium and neuropsychiatric therapeutics: Neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 110(1): 14-28.
40. Wright LL, Beck C, Perez-Polo JR. 1987. Sex differences in nerve growth factor levels in superior cervical ganglia and pineals. Int J Dev Neurosci 5(5-6): 383-390.